VYNE VYNE Therapeutics Inc. Stock Quote

VYNE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.43	Insider Own	3.10%	Shs Outstand	53.55M	Perf Week	5.40%
Market Cap	20.89M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	0.78%	Shs Float	52.72M	Perf Month	-19.00%
Income	-73.30M	PEG	-	EPS next Q	-0.17	Inst Own	25.50%	Short Float	2.98%	Perf Quarter	-27.31%
Sales	14.80M	P/S	1.41	EPS this Y	81.90%	Inst Trans	0.90%	Short Ratio	2.27	Perf Half Y	-67.50%
Book/sh	0.91	P/B	0.44	EPS next Y	42.60%	ROA	-78.70%	Target Price	5.80	Perf Year	-89.02%
Cash/sh	0.81	P/C	0.49	EPS next 5Y	-	ROE	-123.40%	52W Range	0.34 - 4.24	Perf YTD	-60.80%
Dividend	-	P/FCF	-	EPS past 5Y	11.10%	ROI	-139.10%	52W High	-90.57%	Beta	1.08
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	85.40%	Gross Margin	77.30%	52W Low	17.59%	ATR	0.04
Employees	28	Current Ratio	3.40	Sales Q/Q	-46.50%	Oper. Margin	-	RSI (14)	39.55	Volatility	10.61% 10.11%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	60.60%	Profit Margin	-	Rel Volume	0.53	Prev Close	0.41
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	692.16K	Price	0.40
Recom	2.00	SMA20	-4.72%	SMA50	-26.60%	SMA200	-61.34%	Volume	365,812	Change	-2.49%

Dec-06-21

Resumed

H.C. Wainwright

Buy

May-18-22 08:00AM	VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference GlobeNewswire
May-12-22 04:05PM	VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
May-10-22 08:00AM	VYNE Hosting Key Opinion Leader Event on Novel InhiBET BET Inhibitor Platform GlobeNewswire
May-06-22 08:00AM	VYNE Therapeutics to Present at LifeSci Partners Immunology & Inflammation Symposium on May 10th GlobeNewswire
May-05-22 02:06PM	Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky Simply Wall St. -5.48%
Apr-28-22 03:02PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -5.15%
Apr-07-22 08:00AM	VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis GlobeNewswire +9.51%
Mar-30-22 08:00AM	VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis GlobeNewswire +7.02%
Mar-17-22 08:00AM	VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update GlobeNewswire +6.09%
Mar-07-22 07:00AM	VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo GlobeNewswire
Mar-03-22 08:00AM	VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference GlobeNewswire -5.32%
Jan-19-22 08:00AM	VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis GlobeNewswire
Jan-13-22 07:00AM	VYNE Therapeutics Divests Topical Minocycline Assets GlobeNewswire -21.45%
Jan-03-22 08:00AM	VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event GlobeNewswire +10.78%
Dec-13-21 12:08PM	Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't? Zacks -18.67%
Nov-18-21 08:00AM	VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire -5.13%
Nov-12-21 01:09PM	VYNE Therapeutics (NASDAQ:VYNE) investors are sitting on a loss of 80% if they invested a year ago Simply Wall St.
Nov-10-21 07:30AM	VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Nov-04-21 08:00AM	Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study GlobeNewswire
Oct-28-21 03:05PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
08:00AM	VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021 GlobeNewswire
Oct-26-21 08:00AM	Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies GlobeNewswire +14.41%
Oct-21-21 08:00AM	VYNE Therapeutics Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-19-21 08:00AM	VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis GlobeNewswire
Oct-05-21 08:00AM	VYNE Therapeutics Announces its China Partners Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne GlobeNewswire -5.56%
Sep-20-21 08:00AM	VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference GlobeNewswire -5.73%
Sep-08-21 08:00AM	VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference GlobeNewswire
Aug-13-21 07:11AM	Revenue Downgrade: Here's What Analysts Forecast For VYNE Therapeutics Inc. (NASDAQ:VYNE) Simply Wall St. -10.55%
Aug-12-21 07:30AM	VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases GlobeNewswire -31.14%
07:00AM	VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited GlobeNewswire
Aug-11-21 08:43AM	Are Institutions Heavily Invested In VYNE Therapeutics Inc.'s (NASDAQ:VYNE) Shares? Simply Wall St. +5.47%
Aug-05-21 03:01PM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Aug-02-21 08:00AM	VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone GlobeNewswire
Jul-27-21 08:00AM	VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 GlobeNewswire
Jul-19-21 08:00AM	VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne GlobeNewswire
Jun-29-21 08:00AM	VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event GlobeNewswire
Jun-08-21 09:34AM	VYNE Therapeutics Inc.'s (NASDAQ:VYNE) Profit Outlook Simply Wall St.
May-06-21 07:00AM	VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire -21.24%
Apr-28-21 08:00AM	VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021 GlobeNewswire
Apr-22-21 08:14AM	VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year. Simply Wall St.
Mar-04-21 04:01PM	VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences GlobeNewswire -9.73%
07:00AM	VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update GlobeNewswire
06:30AM	VYNE Therapeutics Inc to Host Earnings Call ACCESSWIRE
Mar-01-21 04:01PM	VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference GlobeNewswire
08:00AM	VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis GlobeNewswire
Feb-18-21 10:16AM	Here are the tough questions Congress needs to ask about GameStop today Yahoo Finance Video -5.64%
Feb-17-21 12:46AM	What You Need To Know About The VYNE Therapeutics Inc. (NASDAQ:VYNE) Analyst Downgrade Today Simply Wall St. -10.57%
Feb-16-21 12:02PM	What the GameStop Congressional hearing will reveal to retail investors Yahoo Finance
Feb-11-21 08:00AM	VYNE Therapeutics Announces Reverse Stock Split GlobeNewswire -9.52%
Feb-01-21 08:00AM	VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update GlobeNewswire +16.16%
Jan-29-21 08:00AM	VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update GlobeNewswire -11.21%
Jan-26-21 07:59AM	VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire -5.30%
Jan-21-21 08:00AM	VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company GlobeNewswire
Jan-05-21 08:00AM	VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week GlobeNewswire
Dec-24-20 05:53AM	VYNE Therapeutics Inc. (NASDAQ:VYNE): Are Analysts Optimistic? Simply Wall St.
Dec-17-20 08:00AM	VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne GlobeNewswire
Dec-16-20 08:00AM	VYNE Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-15-20 08:00AM	VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4% GlobeNewswire
Dec-09-20 10:29PM	Is VYNE A Good Stock To Buy Now? Insider Monkey
Dec-01-20 08:00AM	VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology GlobeNewswire
Nov-25-20 08:00AM	VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference GlobeNewswire
Nov-09-20 12:47PM	US$7.07 - That's What Analysts Think VYNE Therapeutics Inc. (NASDAQ:VYNE) Is Worth After These Results Simply Wall St.
Nov-05-20 07:00AM	VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-28-20 08:00AM	VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th GlobeNewswire -9.44%
Oct-07-20 08:01AM	VYNE Therapeutics Announces Covered Status for ZILXI (minocycline) with Express Scripts PR Newswire +8.00%
08:00AM	VYNE Therapeutics Announces Covered Status for ZILXI (minocycline) with Express Scripts GlobeNewswire
Oct-01-20 07:01AM	VYNE Therapeutics Announces ZILXI (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st PR Newswire
07:00AM	VYNE Therapeutics Announces ZILXI (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st GlobeNewswire
Sep-24-20 10:46AM	3 Strong Buy Healthcare Stocks Under $5 With Triple-Digit Growth Prospects TipRanks +6.58%
Sep-23-20 08:00AM	VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI GlobeNewswire -10.59%
Sep-14-20 08:00AM	VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors GlobeNewswire +9.27%
Sep-11-20 08:35AM	Market Morning: Brexit Bill Anger, Gilead Fights ICER, Big Apple Rots Market Exclusive
Sep-09-20 02:56PM	What You Need To Know About Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Investor Composition Simply Wall St.
08:00AM	VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September GlobeNewswire

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEPORE PATRICK G	Director	Nov 30	Buy	1.02	12,500	12,699	62,500	Dec 02 05:08 PM
LEPORE PATRICK G	Director	Aug 25	Buy	1.60	12,500	20,000	50,000	Aug 26 05:04 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 16	Sale	1.74	250,000	435,000	4,935,057	Aug 18 07:19 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 13	Sale	1.84	250,000	460,000	5,185,057	Aug 17 04:46 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 12	Sale	2.23	338,897	755,740	5,435,057	Aug 16 06:24 PM
LEPORE PATRICK G	Director	May 26	Buy	3.60	12,500	44,958	37,500	May 27 05:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience